Kristen S. Hobbs

Kristen S. Hobbs

Auto-generated profile, based on publicly available information

Kristen S. Hobbs

Division of Biology Kansas State University Manhattan Kansas USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
THTimothy J Henrich
Timothy J Henrich
HHHiroyu Hatano
Hiroyu Hatano
OBOliver Bacon
Oliver Bacon
LHLouise E Hogan
Louise E Hogan
RRRachel Rutishauser
Rachel Rutishauser
SDSteven G Deeks
Steven G Deeks
It is unknown if extremely early initiation of antiretroviral therapy (ART) may lead to long-term ART-free HIV remission or cure. As a result, we studied 2 individuals recruited from a pre-exposure prophylaxis (PrEP) program who started prophylactic ART an estimated 10 days (Participant A; 54-year-old male) and 12 days (Participant B; 31-year-old male) after infection with peak plasma HIV RNA of 220 copies/mL and 3,343 copies/mL, respectively. Extensive testing of blood and tissue for HIV persistence was performed, and PrEP Participant A underwent analytical treatment interruption (ATI) following 32 weeks of continuous ART. Colorectal and lymph node tissues, bone marrow, cerebral spinal fluid (CSF), plasma, and very large numbers of peripheral blood mononuclear cells (PBMCs) were obtained longitudinally from both participants and were studied for HIV persistence in several laboratories using molecular and culture-based detection methods, including a murine viral outgrowth assay (mVOA). Both participants initiated PrEP with tenofovir/emtricitabine during very early Fiebig stage I (detectable plasma HIV-1 RNA, antibody negative) followed by 4-drug ART intensification. Following peak viral loads, both participants experienced full suppression of HIV-1 plasma viremia. Over the following 2 years, no further HIV could be detected in blood or tissue from PrEP Participant A despite extensive sampling from ileum, rectum, lymph nodes, bone marrow, CSF, circulating CD4+ T cell subsets, and plasma. No HIV was detected from tissues obtained from PrEP Participant B, but low-level HIV RNA or DNA was intermittently detected from various CD4+ T cell subsets. Over 500 million CD4+ T cells were assayed from both participants in a humanized mouse outgrowth assay. Three of 8 mice infused with CD4+ T cells from PrEP Participant B developed viremia (50 million input cells/surviving mouse), but only 1 of 10 mice infused with CD4+ T cells from PrEP Participant A (53 million input cells/mouse) experienced very low level viremia (201 copies/mL); sequence confirmation was unsuccessful. PrEP Participant A stopped ART and remained aviremic for 7.4 months, rebounding with HIV RNA of 36 copies/mL that rose to 59,805 copies/mL 6 days later. ART was restarted promptly. Rebound plasma HIV sequences were identical to those obtained during acute infection by single-genome sequencing. Mathematical modeling predicted that the latent reservoir size was approximately 200 cells prior to ATI and that only around 1% of individuals with a similar HIV burden may achieve lifelong ART-free remission. Furthermore, we observed that lymphocytes expressing the tumor marker CD30 increased in frequency weeks to months prior to detectable HIV-1 RNA in plasma. This study was limited by the small sample size, which was a result of the rarity of individuals presenting during hyperacute infection. We report HIV relapse despite initiation of ART at one of the earliest stages of acute HIV infection possible. Near complete or complete loss of detectable HIV in blood and tissues did not lead to indefinite ART-free HIV remission. However, the small numbers of latently infected cells in individuals treated during hyperacute infection may be associated with prolonged ART-free remission.

22 February 2018 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
LHLouise E Hogan
Louise E Hogan
JVJoshua Vasquez
Joshua Vasquez
KHKristen S Hobbs
Kristen S Hobbs
EHEmily Hanhauser
Emily Hanhauser
BABrandon Aguilar-Rodriguez
Brandon Aguilar-Rodriguez
THTimothy J Henrich
Timothy J Henrich
HIV-1-infected cells persist indefinitely despite the use of combination antiretroviral therapy (ART), and novel therapeutic strategies to target and purge residual infected cells in individuals on ART are urgently needed. Here, we demonstrate that CD4+ T cell-associated HIV-1 RNA is often highly enriched in cells expressing CD30, and that cells expressing this marker considerably contribute to the total pool of transcriptionally active CD4+ lymphocytes in individuals on suppressive ART. Using in situ RNA hybridization studies, we show co-localization of CD30 with HIV-1 transcriptional activity in gut-associated lymphoid tissues. We also demonstrate that ex vivo treatment with brentuximab vedotin, an antibody-drug conjugate (ADC) that targets CD30, significantly reduces the total amount of HIV-1 DNA in peripheral blood mononuclear cells obtained from infected, ART-suppressed individuals. Finally, we observed that an HIV-1-infected individual, who received repeated brentuximab vedotin infusions for lymphoma, had no detectable virus in peripheral blood mononuclear cells. Overall, CD30 may be a marker of residual, transcriptionally active HIV-1 infected cells in the setting of suppressive ART. Given that CD30 is only expressed on a small number of total mononuclear cells, it is a potential therapeutic target of persistent HIV-1 infection. Previous studies have shown that higher levels of soluble CD30 are associated with HIV-1 disease progression. Many of these studies, however, were performed prior to the implementation of combination ART, and the relationship between surface CD30 expression, soluble CD30 and HIV-1 infection in ART suppressed individuals, or those with viremic control off ART, is not known. We demonstrate that cell-associated HIV-1 RNA is highly enriched in CD4+ T cells expressing CD30, a member of the tumor necrosis factor receptor superfamily. These findings were observed in several HIV-1 infected donor groups, regardless of whether or not the participants were receiving suppressive ART. Furthermore, we demonstrate that ex vivo treatment with brentuximab vedotin, an antibody-drug conjugate that targets CD30, reduces the total amount of HIV-1 DNA in PBMC obtained from infected individuals. Finally, we show through in situ RNA hybridization studies that CD30 and HIV transcriptional activity co-localize in cells from gut biopsies obtained from HIV-1 infected donors. These data suggest that CD30 may be a marker of residual, transcriptionally active HIV-1 infected cells in the setting of suppressive ART.

1 June 2023 in Animal Behaviour
Verified
Journal Article
Closed access
SBSarah E. E. Bush
Sarah E. E. Bush
MWMadison Waller
Madison Waller
JHJordan M. Herman
Jordan M. Herman
KHKristen S. Hobbs
Kristen S. Hobbs
ACAustin R. Clayton
Austin R. Clayton
DCDale H. Clayton
Dale H. Clayton

27 November 2024 in Ibis
Verified
Journal Article
Open access
ESElizabeth N. Sroor
Elizabeth N. Sroor
WBW. Alice Boyle
W. Alice Boyle
HCHenry N. Castro‐Miller
Henry N. Castro‐Miller
KHKristen S. Hobbs
Kristen S. Hobbs
MRMiriam D. Reynaldo
Miriam D. Reynaldo
NFNikole E. Freeman
Nikole E. Freeman
Female investment in reproduction is a critical component of life history that influences both the fitness of the female and her offspring. Oviparous females can allocate energy into egg size and/or clutch size, and this allocation can vary over lifetimes, within populations and among species. However, we know little about whether investment decisions shift within breeding seasons and the factors that influence female reproductive strategies. We studied endogenous and exogenous factors associated with variation in female reproductive investment by measuring 860 eggs from 240 clutches laid by Grasshopper Sparrows Ammodramus savannarum between 2014 and 2019 at the Konza Prairie Biological Station in Manhattan, Kansas, USA. As the breeding season progressed, females laid smaller clutches of heavier eggs, indicating a shift in investment towards fewer but higher quality young. Females that were heavier than expected given their body size laid heavier and larger eggs, but maternal body condition was not related to clutch size. Brood parasitism by Brown‐headed Cowbirds Molothrus ater reduced the number of Grasshopper Sparrow eggs in nests, but was unrelated to host egg size or the total number of eggs that a female incubated, implying that sparrows do not adjust investment in response to parasitism risk. Pre‐laying ambient temperature and precipitation were not associated with egg size, yet females tended to lay more eggs under rainier conditions. Overall, we provide evidence that both endogenous and exogenous factors shape female reproductive investment. Understanding the flexibility of reproductive strategies in response to multiple sources of selection, and how this mediates key trade‐offs that influence demographic rates, can be used in forecasting population growth of bird species affected by anthropogenic changes to breeding areas.